In Silico Identification of Dysregulated miRNAs Targeting KRAS Gene in Pancreatic Cancer

被引:0
|
作者
Garibaldi-Rios, Asbiel Felipe [1 ,2 ]
Figuera, Luis E. [1 ,2 ]
Zuniga-Gonzalez, Guillermo Moises [3 ]
Gomez-Meda, Belinda Claudia [4 ]
Garcia-Verdin, Patricia Montserrat [1 ,2 ]
Carrillo-Davila, Irving Alejandro [1 ,2 ]
Gutierrez-Hurtado, Itzae Adonai [4 ]
Torres-Mendoza, Blanca Miriam [5 ,6 ]
Gallegos-Arreola, Martha Patricia [1 ]
机构
[1] Inst Mexicano Seguro Social IMSS, Div Genet, Ctr Invest Biomed Occidente CIBO, Ctr Med Nacl Occidente CMNO, Guadalajara 44340, Jalisco, Mexico
[2] Univ Guadalajara UdeG, Ctr Univ Ciencias Salud CUCS, Doctorado Genet Humana, Guadalajara 44340, Jalisco, Mexico
[3] Inst Mexicano Seguro Social IMSS, Div Med Mol, Ctr Invest Biomed Occidente CIBO, Ctr Med Nacl Occidente CMNO, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico
[4] Univ Guadalajara UdeG, Ctr Univ Ciencias Salud CUCS, Dept Biol Mol & Genom, Inst Genet Humana Dr Enr Corona Rivera, Guadalajara 44340, Jalisco, Mexico
[5] Inst Mexicano Seguro Social IMSS, Lab Inmunodeficiencias Humanas & Retrovirus, Div Neurociencias, Ctr Invest Biomed Occidente CIBO, Guadalajara 44340, Jalisco, Mexico
[6] Univ Guadalajara UdeG, Ctr Univ Ciencias Salud CUCS, Dept Disciplinas Filosof Metodologicas, Guadalajara 44340, Jalisco, Mexico
关键词
pancreatic neoplasms; KRAS proto-oncogene; microRNAs; biomarkers; in silico techniques; gene expression regulation; MICRORNA-BINDING SITE; LUNG-CANCER; RS712; POLYMORPHISM; EXPRESSION; ASSOCIATION; CARCINOMA; MIR-30A-5P; RISK; PROLIFERATION; RS61764370;
D O I
10.3390/diseases12070152
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pancreatic cancer (PC) is highly lethal, with KRAS mutations in up to 95% of cases. miRNAs inversely correlate with KRAS expression, indicating potential as biomarkers. This study identified miRNAs targeting KRAS and their impact on PC characteristics using in silico methods. dbDEMC identified dysregulated miRNAs in PC; TargetScan, miRDB, and PolymiRTS 3.0 identified miRNAs specific for the KRAS gene; and OncomiR evaluated the association of miRNAs with clinical characteristics and survival in PC. The correlation between miRNAs and KRAS was analysed using ENCORI/starBase. A total of 210 deregulated miRNAs were identified in PC (116 overexpressed and 94 underexpressed). In total, 16 of them were involved in the regulation of KRAS expression and 9 of these (hsa-miR-222-3p, hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-miR-30e-5p, hsa-miR-377-3p, hsa-miR-495-3p, hsa-miR-654-3p, hsa-miR-877-5p and hsa-miR-885-5p) were associated with the clinical characteristics of the PC. Specifically, the overexpression of hsa-miR-30a-5p was associated with PC mortality, and hsa-miR-30b-5p, hsa-miR-377-3p, hsa-miR-495-3p, and hsa-miR-885-5p were associated with survival. Correlation analysis revealed that the expression of 10 miRNAs is correlated with KRAS expression. The dysregulated miRNAs identified in PC may regulate KRAS and some are associated with clinically relevant features, highlighting their potential as biomarkers and therapeutic targets in PC treatment. However, experimental validation is required for confirmation.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Targeting KRAS in Pancreatic Cancer
    Cowzer, Darren
    Zameer, Mohammed
    Conroy, Michael
    Kolch, Walter
    Duffy, Austin G.
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (11):
  • [2] Targeting KRAS in pancreatic cancer
    Stickler, Sandra
    Rath, Barbara
    Hamilton, Gerhard
    ONCOLOGY RESEARCH, 2024, 32 (05) : 799 - 805
  • [3] Targeting miRNAs for Pancreatic Cancer Therapy
    Shi, Min
    Xie, Dacheng
    Gao, Yong
    Xie, Keping
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (33) : 5279 - 5286
  • [4] Targeting KRAS for pancreatic cancer treatment
    Der, Channing J.
    CANCER RESEARCH, 2024, 84 (17)
  • [5] Targeting Oncogenic KRAS in Pancreatic Cancer
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (04) : 569 - 569
  • [6] PANCREATIC CANCER Exosomes for targeting KRAS in the treatment of pancreatic cancer
    Buscail, Louis
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (11) : 636 - 637
  • [7] Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer
    Bear, Adham S.
    Rech, Andrew J.
    Richman, Lee P.
    O'Hara, Mark H.
    Linette, Gerald P.
    Carreno, Beatriz M.
    Vonderheide, Robert H.
    CANCER RESEARCH, 2019, 79 (24)
  • [8] Targeting KRAS in Pancreatic Cancer by Gene Silencing with U1 Adaptors
    Tsang, Ashley T.
    Yu, Xin
    Goraczniak, Rafal
    Brenneman, Mark
    Gunderson, Samuel
    Carpizo, Darren R.
    MOLECULAR THERAPY, 2015, 23 : S276 - S277
  • [9] Exosomes for targeting KRAS in the treatment of pancreatic cancer
    Louis Buscail
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 636 - 638
  • [10] In silico identification of multidrug resistance gene (MDR)-targeted transposon miRNAs in human cancer
    Mesci, Seda
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2025, 830